Mark Schmidt to Biomarkers
This is a "connection" page, showing publications Mark Schmidt has written about Biomarkers.
Connection Strength
0.758
-
Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimers Dement. 2021 07; 17(7):1189-1204.
Score: 0.165
-
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. Alzheimers Dement. 2020 05; 16(5):750-758.
Score: 0.154
-
Serum Biomarkers Indicate Long-term Reduction in Liver Fibrosis in Patients With Sustained Virological Response to Treatment for HCV Infection. Clin Gastroenterol Hepatol. 2016 07; 14(7):1044-1055.e3.
Score: 0.115
-
APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat. 2014 Dec; 21(12):917-20.
Score: 0.104
-
The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014 Dec; 21(12):930-7.
Score: 0.100
-
Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis. J Gastroenterol Hepatol. 2025 Sep; 40(9):2209-2218.
Score: 0.055
-
A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C. Dig Dis Sci. 2017 11; 62(11):3221-3234.
Score: 0.032
-
Long-term progression of viral load and serum markers of fibrosis among treated and untreated patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017 Jun; 32(6):1250-1257.
Score: 0.032